retatrutide nombre comercial Advertencia Sanitaria sobre Promoción y Aplicación de Medicamentos Inyectables para Bajar de Peso en Clínicas de Nutrición Retatrutida 10 mg México |

In clinical trials, participants receiving 12 mg weekly retatrutide lost an average of 24% of their body weight over 48 weeks [2]

The dual action of Tirzepatide effectively reduces caloric intake while improving glucose metabolism, which explains why the SURMOUNT-1 trial data showed up to a 22.5% mean weight reduction at the 72-week mark

When you take a GLP-1 agonist, food stays in your stomach longer

It is part of a new class of incretin-based medications and functions as a triple agonist, unlike its peers like tirzepatide, which act only as dual agonists

Phase 2 trial data shows promising efficacy but is insufficient to confirm long-term safety

Safety Profile: Observed effects are consistent with the incretin class, including manageable gastrointestinal transitions such as nausea or mild digestive changes